-
1
-
-
37549049805
-
Skipping toward personalized molecular medicine
-
Hoffman EP Skipping toward personalized molecular medicine. N Engl J Med. 2007 ; 357: 2719-2722.
-
(2007)
N Engl J Med
, vol.357
, pp. 2719-2722
-
-
Hoffman, E.P.1
-
2
-
-
33947712686
-
Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers
-
Trusheim MR, Berndt ER, Douglas FL Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007 ; 6: 287-293.
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 287-293
-
-
Trusheim, M.R.1
Berndt, E.R.2
Douglas, F.L.3
-
3
-
-
33747874300
-
The path from genome-based research to population health: Development of an international public health genomics network
-
Burke W., Khoury MJ, Stewart A., Zimmern RL ; Bellagio Group. The path from genome-based research to population health: development of an international public health genomics network. Genet Med. 2006 ; 8: 451-458.
-
(2006)
Genet Med
, vol.8
, pp. 451-458
-
-
Burke, W.1
Khoury, M.J.2
Stewart, A.3
Zimmern, R.L.4
Group, B.5
-
4
-
-
34248358677
-
How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach
-
Williams I., Bryan S., McIver S. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach. J Health Serv Res Policy. 2007 ; 12: 73-79.
-
(2007)
J Health Serv Res Policy
, vol.12
, pp. 73-79
-
-
Williams, I.1
Bryan, S.2
McIver, S.3
-
5
-
-
24644490720
-
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. Preventive Services Task Force
-
Nelson HD, Huffman LH, Fu R., Harris EL Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2005 ; 143: 362-379.
-
(2005)
Ann Intern Med.
, vol.143
, pp. 362-379
-
-
Nelson, H.D.1
Huffman, L.H.2
Fu, R.3
Harris, E.L.4
-
6
-
-
41149120561
-
A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions
-
Janssens AC, Gwinn M., Bradley LA, Oostra BA, van Duijn CM, Khoury MJ A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet. 2008 ; 82: 593-599.
-
(2008)
Am J Hum Genet
, vol.82
, pp. 593-599
-
-
Janssens, A.C.1
Gwinn, M.2
Bradley, L.A.3
Oostra, B.A.4
Van Duijn, C.M.5
Khoury, M.J.6
-
8
-
-
33749332084
-
Coverage options for promising technologies: Medicares coverage with evidence development
-
Millwood).
-
Tunis SR, Pearson SD Coverage options for promising technologies: Medicares coverage with evidence development. Health Aff (Millwood). 2006 ; 25: 1218-1230.
-
(2006)
Health Aff
, vol.25
, pp. 1218-1230
-
-
Tunis, S.R.1
Pearson, S.D.2
-
9
-
-
37349116252
-
The continuum of translation research in genomic medicine: How can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention
-
Khoury MJ, Gwinn M., Yoon PW, Dowling N., Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention ? Genet Med. 2007 ; 9: 665-674.
-
(2007)
Genet Med
, vol.9
, pp. 665-674
-
-
Khoury, M.J.1
Gwinn, M.2
Yoon, P.W.3
Dowling, N.4
Moore, C.A.5
Bradley, L.6
-
10
-
-
0034770853
-
Categorizing genetic tests to identify their ethical, legal, and social implications
-
Burke W., Pinsky LE, Press NA Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Genet. 2001 ; 106: 233-240.
-
(2001)
Am J Med Genet
, vol.106
, pp. 233-240
-
-
Burke, W.1
Pinsky, L.E.2
Press, N.A.3
-
11
-
-
84871804875
-
-
Evaluation of Genomic Applications In Practice (egapp)
-
Evaluation of Genomic Applications in Practice and Prevention (EGAPP): Implementation and Evaluation of a Model Approach. Available from: http://www.egappreviews.org/about.htm
-
Implementation and Evaluation of A Model Approach
-
-
-
12
-
-
59849108152
-
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group
-
Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP Working Group. Genet Med. 2009 ; 11: 3-14.
-
(2009)
Genet Med
, vol.11
, pp. 3-14
-
-
Teutsch, S.M.1
Bradley, L.A.2
Palomaki, G.E.3
-
13
-
-
20444374342
-
ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests
-
Khoury MJ, Little J, Burke W, eds. New York: Oxford University Press
-
Haddow JE, Palomaki GE ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W, eds. Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford University Press ; 2004. p 217-233.
-
(2004)
Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease
, pp. 217-233
-
-
Haddow, J.E.1
Palomaki, G.E.2
-
14
-
-
33747878216
-
What is the clinical utility of genetic testing
-
Grosse SD, Khoury MJ What is the clinical utility of genetic testing ? Genet Med. 2006 ; 8: 448-450.
-
(2006)
Genet Med
, vol.8
, pp. 448-450
-
-
Grosse, S.D.1
Khoury, M.J.2
-
15
-
-
37349093041
-
Recommendations from the EGAPP Working Group: Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors
-
Evaluation Of Genomic Applications In Practice(egapp)
-
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med. 2007 ; 9: 819-825.
-
(2007)
Genet Med.
, vol.9
, pp. 819-825
-
-
-
16
-
-
59849117793
-
Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
-
Evaluation Of Genomic Applications In Practice (egapp)
-
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med. 2009 ; 11: 15-20.
-
(2009)
Genet Med
, vol.11
, pp. 15-20
-
-
-
17
-
-
59849108362
-
Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives
-
Evaluation of Genomic Applications In Practice (egapp)
-
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009 ; 11: 35-41.
-
(2009)
Genet Med.
, vol.11
, pp. 35-41
-
-
-
18
-
-
59849127767
-
Recommendations from the EGAPP Working Group: Can tumor gene expression profiling improve outcomes in patients with breast cancer?
-
Evaluation of Genomic Applications In Practice (egapp) Working Group .
-
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med. 2009 ; 11: 66-73.
-
(2009)
Genet Med
, vol.11
, pp. 66-73
-
-
-
19
-
-
0003716539
-
-
Rockville, MD : US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)
-
Food and Drug Administration. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) ; 1998. Available from: www.fda.gov
-
(1998)
Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drugs and Biological Products
-
-
-
20
-
-
33750106228
-
National surveillance of emergency department visits for outpatient adverse drug events
-
Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006 ; 296: 1858-1866.
-
(2006)
JAMA
, vol.296
, pp. 1858-1866
-
-
Budnitz, D.S.1
Pollock, D.A.2
Weidenbach, K.N.3
Mendelsohn, A.B.4
Schroeder, T.J.5
Annest, J.L.6
-
21
-
-
33644974597
-
Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvularatrial fibrillation: Pooled analysis from the SPORTIF III and v studies
-
Executive Steering Committee of the SPORTIFF III and V Investigators
-
Diener HC ; Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvularatrial fibrillation: pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis. 2006 ; 21: 279-293.
-
(2006)
Cerebrovasc Dis.
, vol.21
, pp. 279-293
-
-
Diener, H.C.1
-
22
-
-
40449120615
-
Genetic determinants of response to warfarin during initial anticoagulation
-
Schwarz UI, Ritchie MD, Bradford Y., et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008 ; 358: 999-1008.
-
(2008)
N Engl J Med
, vol.358
, pp. 999-1008
-
-
Schwarz, U.I.1
Ritchie, M.D.2
Bradford, Y.3
-
23
-
-
45949103309
-
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
-
8th edition).
-
Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8 th edition). Chest. 2008 ; 133: 160S - 98S.
-
(2008)
Chest
, vol.133
-
-
Ansell, J.1
Hirsh, J.2
Hylek, E.3
-
24
-
-
49949098665
-
The critical path of warfarin dosing: Finding an optimal dosing strategy using pharmacogenetics
-
Lesko LJ The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther. 2008 ; 84: 301-303.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 301-303
-
-
Lesko, L.J.1
-
25
-
-
34147162376
-
Pharmacogenetics of warfarin: Current status and future challenges
-
Wadelius M., Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. J Pharmacogenomics. 2007 ; 7: 99-111.
-
(2007)
J Pharmacogenomics
, vol.7
, pp. 99-111
-
-
Wadelius, M.1
Pirmohamed, M.2
-
26
-
-
47949086046
-
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
-
Gage BF, Eby C., Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 ; 84: 326-331.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 326-331
-
-
Gage, B.F.1
Eby, C.2
Johnson, J.A.3
-
27
-
-
38349126516
-
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin
-
Limdi NA, McGwin G., Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther. 2008 ; 83: 312-321.
-
(2008)
Clin Pharmacol Ther
, vol.83
, pp. 312-321
-
-
Limdi, N.A.1
McGwin, G.2
Goldstein, J.A.3
-
28
-
-
39449137238
-
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
-
Flockhart DA, OKane D., Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008 ; 10: 139-150.
-
(2008)
Genet Med.
, vol.10
, pp. 139-150
-
-
Flockhart, D.A.1
Okane, D.2
Williams, M.S.3
-
29
-
-
49949108046
-
Warfarin and pharmacogenomic testing: The case for restraint
-
Garcia DA Warfarin and pharmacogenomic testing: the case for restraint. Clin Pharmacol Ther. 2008 ; 84: 303-305.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 303-305
-
-
Garcia, D.A.1
-
30
-
-
50249121818
-
Genetic testing for warfarin therapy initiation
-
Hynicka LM, Cahoon WD Jr, Bukaveckas BL Genetic testing for warfarin therapy initiation. Ann Pharmacother. 2008 ; 42: 1298-1303.
-
(2008)
Ann Pharmacother
, vol.42
, pp. 1298-1303
-
-
Hynicka, L.M.1
Bukaveckas, B.L.2
-
32
-
-
36549030324
-
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
-
Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 ; 116: 2563-2570.
-
(2007)
Circulation
, vol.116
, pp. 2563-2570
-
-
Anderson, J.L.1
Horne, B.D.2
Stevens, S.M.3
-
33
-
-
39449086981
-
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study
-
Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008 ; 83: 460-470.
-
(2008)
Clin Pharmacol Ther
, vol.83
, pp. 460-470
-
-
Caraco, Y.1
Blotnick, S.2
Muszkat, M.3
-
34
-
-
60849097257
-
Estimation of the warfarin dose with clinical and pharmacogenetic data
-
Klein TE, Altman RB, Eriksson N., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 ; 360: 753-764.
-
(2009)
N Engl J Med
, vol.360
, pp. 753-764
-
-
Klein, T.E.1
Altman, R.B.2
Eriksson, N.3
-
36
-
-
77952995034
-
Section 1.3: Evidence for Pharmacogenomic Tests and Drugs
-
Academy of Managed Care Pharmacy
-
Academy of Managed Care Pharmacy. Section 1.3: Evidence for pharmacogenomic tests and drugs. In: The AMCP Format for Formulary Submissions. Version 2.1, April 2005. Available from: http://www.fmcpnet.org/index.cfm?pl= A0EE1897
-
(2005)
The AMCP Format for Formulary Submissions. Version 2.1
-
-
-
37
-
-
77952987653
-
Medco warfarin, tamoxifen genomic testing finding traction among payers
-
Kelly C. Medco warfarin, tamoxifen genomic testing finding traction among payers. The Pink Sheet. 2 December 2008. Available from: http://www. biopharmatoday.com/2008/12/medco-warfarin-tamoxifen-genomic-testing-finding- traction-among-payers.html
-
(2008)
The Pink Sheet
-
-
Kelly, C.1
-
39
-
-
46949100710
-
Assessing cost-effectiveness in healthcare: History of the USD 50,000 per QALY threshold
-
Grosse SD Assessing cost-effectiveness in healthcare: history of the USD 50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008 ; 8: 165-178.
-
(2008)
Expert Rev Pharmacoecon Outcomes Res
, vol.8
, pp. 165-178
-
-
Grosse, S.D.1
-
40
-
-
57349096844
-
Saying no isnt NICE: The travails of Britains National Institute for Health and Clinical Excellence
-
Steinbrook R. Saying no isnt NICE: the travails of Britains National Institute for Health and Clinical Excellence. N Engl J Med. 2008 ; 359: 1977-1981.
-
(2008)
N Engl J Med
, vol.359
, pp. 1977-1981
-
-
Steinbrook, R.1
-
41
-
-
33749334735
-
Linking pharmacogenetics-based diagnostics and drugs for personalized medicine
-
Millwood).
-
Garrison LP Jr, Austin MJ Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Aff (Millwood). 2006 ; 25: 1281-1290.
-
(2006)
Health Aff
, vol.25
, pp. 1281-1290
-
-
Austin, M.J.1
-
42
-
-
34548062005
-
The cost-effectiveness of warfarin pharmacogenomics
-
Veenstra DL The cost-effectiveness of warfarin pharmacogenomics. J Thromb Haemost. 2007 ; 5: 1974-1975.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 1974-1975
-
-
Veenstra, D.L.1
-
43
-
-
33947357078
-
Current use of pharmacogenetic testing: A national survey of thiopurinemethyltransferase testing prior to azathioprine prescription
-
Fargher EA, Tricker K., Newman W., et al. Current use of pharmacogenetic testing: a national survey of thiopurinemethyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther. 2007 ; 32: 187-195.
-
(2007)
J Clin Pharm Ther
, vol.32
, pp. 187-195
-
-
Fargher, E.A.1
Tricker, K.2
Newman, W.3
-
44
-
-
34248594708
-
Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis
-
Millwood).
-
Garrison LP Jr, Towse A., Bresnahan BW Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood). 2007 ; 26: 684-695.
-
(2007)
Health Aff
, vol.26
, pp. 684-695
-
-
Towse, A.1
Bresnahan, B.W.2
-
45
-
-
35348858847
-
Coverage with evidence development: An examination of conceptual and policy issues
-
Hutton J., Trueman P., Henshall C. Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007 ; 23: 425-432.
-
(2007)
Int J Technol Assess Health Care
, vol.23
, pp. 425-432
-
-
Hutton, J.1
Trueman, P.2
Henshall, C.3
-
46
-
-
49249098731
-
Coverage with evidence development: Ethical issues and policy implications
-
Miller FG, Pearson SD Coverage with evidence development: ethical issues and policy implications. Med Care. 2008 ; 46: 746-751.
-
(2008)
Med Care
, vol.46
, pp. 746-751
-
-
Miller, F.G.1
Pearson, S.D.2
-
49
-
-
33846995628
-
Economics of new oncology drug development
-
DiMasi JA, Grabowski HG Economics of new oncology drug development. J Clin Oncol. 2007 ; 25: 209-216.
-
(2007)
J Clin Oncol
, vol.25
, pp. 209-216
-
-
Dimasi, J.A.1
Grabowski, H.G.2
-
50
-
-
33645675960
-
Estimating the cost of new drug development: Is it really 802 million dollars
-
Millwood).
-
Adams CP, Brantner VV Estimating the cost of new drug development: is it really 802 million dollars ? Health Aff (Millwood). 2006 ; 25: 420-428.
-
(2006)
Health Aff
, vol.25
, pp. 420-428
-
-
Adams, C.P.1
Brantner, V.V.2
-
51
-
-
44049106563
-
Cost of care for elderly cancer patients in the United States
-
Yabroff KR, Lamont EB, Mariotto A., et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008 ; 100: 630-641.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 630-641
-
-
Yabroff, K.R.1
Lamont, E.B.2
Mariotto, A.3
-
52
-
-
77952986714
-
-
Herper M. Cancers cost crisis. Forbes 8 June 2004. Available from: www.forbes.com/technology/2004/06/08/cx-mh-0608costs.html
-
(2004)
Cancers Cost Crisis
-
-
Herper, M.1
-
54
-
-
0030281042
-
An economic approach to clinical trial design and research priority setting
-
Claxton KP, Posnett J. An economic approach to clinical trial design and research priority setting. Health Econ. 1996 ; 5: 513-534.
-
(1996)
Health Econ
, vol.5
, pp. 513-534
-
-
Claxton, K.P.1
Posnett, J.2
-
55
-
-
34548602954
-
Clinical decision making and the expected value of information
-
Willan AR Clinical decision making and the expected value of information. Clin Trials 2007 ; 4: 279-285.
-
(2007)
Clin Trials
, vol.4
, pp. 279-285
-
-
Willan, A.R.1
-
56
-
-
33750600068
-
Using value of information analysis to prioritize health research: Some lessons from recent UK experience
-
Claxton KP, Sculpher MJ Using value of information analysis to prioritize health research: some lessons from recent UK experience. Pharmacoeconomics 2006 ; 24: 1055-1068.
-
(2006)
Pharmacoeconomics
, vol.24
, pp. 1055-1068
-
-
Claxton, K.P.1
Sculpher, M.J.2
-
57
-
-
57149085867
-
Prioritizing future research on off-label prescribing: Results of a quantitative evaluation
-
Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D., Stafford RS Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008 ; 28: 1443-1452.
-
(2008)
Pharmacotherapy
, vol.28
, pp. 1443-1452
-
-
Walton, S.M.1
Schumock, G.T.2
Lee, K.V.3
Alexander, G.C.4
Meltzer, D.5
Stafford, R.S.6
-
58
-
-
34147098358
-
Value of information on preference heterogeneity and individualized care
-
Basu A., Meltzer D. Value of information on preference heterogeneity and individualized care. Med Decis Making. 2007 ; 27: 112-127.
-
(2007)
Med Decis Making
, vol.27
, pp. 112-127
-
-
Basu, A.1
Meltzer, D.2
-
59
-
-
40949153489
-
Ancillary risk information and pharmacogenetic tests: Social and policy implications
-
Henrikson NB, Burke W., Veenstra DL Ancillary risk information and pharmacogenetic tests: social and policy implications. Pharmacogenomics J. 2008 ; 8: 85-89.
-
(2008)
Pharmacogenomics J
, vol.8
, pp. 85-89
-
-
Henrikson, N.B.1
Burke, W.2
Veenstra, D.L.3
-
60
-
-
41449119213
-
Cancer genetics evaluation: Barriers to and improvements for referral
-
Brandt R., Ali Z., Sabel A., McHugh T., Gilman P. Cancer genetics evaluation: barriers to and improvements for referral. Genet Test. 2008 ; 12: 9-12.
-
(2008)
Genet Test
, vol.12
, pp. 9-12
-
-
Brandt, R.1
Ali, Z.2
Sabel, A.3
McHugh, T.4
Gilman, P.5
-
61
-
-
58149239796
-
Legal update: Living with the Genetic Information Nondiscrimination Act
-
Erwin C. Legal update: living with the Genetic Information Nondiscrimination Act. Genet Med. 2008 ; 10: 869-873.
-
(2008)
Genet Med
, vol.10
, pp. 869-873
-
-
Erwin, C.1
-
62
-
-
33646152480
-
The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes
-
Huang ES, Shook M., Jin L., Chin MH, Meltzer DO The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care. 2006 ; 29: 259-264.
-
(2006)
Diabetes Care
, vol.29
, pp. 259-264
-
-
Huang, E.S.1
Shook, M.2
Jin, L.3
Chin, M.H.4
Meltzer, D.O.5
-
63
-
-
58249093641
-
Economic methods for valuing the outcomes of genetic testing: Beyond cost-effectiveness analysis
-
Grosse SD, Wordsworth S., Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med. 2008 ; 10: 648-654.
-
(2008)
Genet Med
, vol.10
, pp. 648-654
-
-
Grosse, S.D.1
Wordsworth, S.2
Payne, K.3
-
64
-
-
40849120194
-
Can pharmacoeconomics and outcomes research contribute to the empowerment of women affected by breast cancer
-
Lee JT, Bridges JFP, Shockney L. Can pharmacoeconomics and outcomes research contribute to the empowerment of women affected by breast cancer ? Exp Rev Pharmacoeconomics Outcomes Res. 2008 ; 8: 73-79.
-
(2008)
Exp Rev Pharmacoeconomics Outcomes Res
, vol.8
, pp. 73-79
-
-
Lee, J.T.1
Bridges, J.F.P.2
Shockney, L.3
-
65
-
-
69549110336
-
Personal utility and genomic information: Look before you leap
-
Grosse SD, McBride CM, Evans J., Khoury MJ Personal utility and genomic information: look before you leap. Genet Med. 2009 Jul 18. [Epub ahead of print].
-
(2009)
Genet Med
-
-
Grosse, S.D.1
McBride, C.M.2
Evans, J.3
Khoury, M.J.4
-
66
-
-
67649732906
-
Challenges of translating genetic tests into clinical and public health practice
-
Rogowski W., Grosse SD, Khoury MJ Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009 ; 10: 489-495.
-
(2009)
Nat Rev Genet
, vol.10
, pp. 489-495
-
-
Rogowski, W.1
Grosse, S.D.2
Khoury, M.J.3
|